J&J trial links anemia drug to patient deaths in stroke trial

09/18/2008 | Google

Preliminary results of a study on Eprex -- an anemia drug developed by Johnson & Johnson's Ortho Biotech unit and sold as Procrit in the U.S. -- showed that more ischemic stroke patients who received the drug died compared with those who received a placebo, the company announced Wednesday. Ortho Biotech said it has notified U.S. and European regulators and is undertaking further analyses of the results.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC